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Rocky Mountain spotted fever (RMSF) is the most severe tickborne infection in the United 
States and is a nationally notifiable disease. Since 1981, the annual case-fatality ratio for 
RMSF has been determined from laboratory-confirmed cases reported to the Centers for 
Disease Control and Prevention (CDC). Herein, a description is given of patients with fatal, 
serologically unconfirmed RMSF for whom a diagnosis of RMSF was established by im- 
munohistochemical (IHC) staining of tissues obtained at autopsy. During 1996-1997, acute- 
phase serum and tissue samples from patients with fatal disease compatible with RMSF were 
tested at the CDC. As determined by indirect immunofluorescence assay, no patient serum 
demonstrated IgG or IgM antibodies reactive with Rickettsia rickettsii at a diagnostic titer 
(i.e., :>64); however, IHC staining confirmed diagnosis of RMSF in all patients. Polymerase 
chain reaction validated the IHC findings for 2 patients for whom appropriate samples were 
available for testing. These findings suggest that dependence on serologic assays and limited 
use of IHC staining for confirmation of fatal RMSF results in underestimates of mortality 
and of case-fatality ratios for this disease. 
The notoriety of Rocky Mountain spotted fever (RMSF) was 
established a century ago when physicians in the northwestern 
United States first reported an acute febrile disease of devas- 
tating severity [1, 2]; during 1885-1912, the mean annual case- 
fatality ratio (CFR) for RMSF in the Bitterroot Valley of west- 
ern Montana exceeded 65% [3]. The profound lethality of 
RMSF continued through the preantibiotic era, and CFRs of 
18.4-28.1 occurred in the United States during 1930-1939 [4, 
5]. Mortality attributable to RMSF plummeted following the 
discovery of effective antirickettsial therapies in the late 1940s, 
and CFRs remained relatively constant at 5%/o-10% for the next 
30 years [6-8]. Since 1981, yearly CFRs have averaged 3.4% 
overall and have dropped to as low as 1.2%. [9] (Centers for 
Disease Control and Prevention [CDC], unpublished ata). The 
numbers of reported RMSF fatalities also declined over this 
period, from a mean of 13 confirmed deaths per year for 
1981-1992 [9] to a mean of 7 confirmed deaths per year for 
1993-1996 (CDC, unpublished data). The reason(s) for the ap- 
parent decline in total reported RMSF fatalities is not known, 
although these changes may be linked to increasing physician 
awareness and earlier diagnosis of tickborne diseases and per- 
haps to concurrent decreases in reporting of RMSE 
Annual reporting of the number of cases of RMSF by state 
health departments has been done since 1920 [10]. Currently, 
cases of RMSF are reported to the CDC via two national 
surveillance systems. The first system was established in 1970 
and consists of standardized case report forms completed by 
private physicians and local or state health department per- 
sonnel. Information submitted through case report forms is 
used by the CDC to periodically compile clinical, epidemio- 
logic, and laboratory summaries of RMSF [7-11]. For sur- 
veillance summaries assembled from case report-form data, 
cases of RMSF are classified as confirmed, probable, or un- 
confirmed according to guidelines established by the Council 
of State and Territorial Epidemiologists [12]. Case classifica- 
tions are made on the basis of results of confirmatory labo- 
ratory tests, which are interpreted in the context of an illness 
clinically compatible with RMSF. 
The second method of national surveillance for RMSF, the 
National Electronic Telecommunications System for Surveil- 
lance (NETSS), was initiated in 1984 to evaluate trends in the 
regional incidence of RMSE NETSS data are accumulated at 
the CDC by weekly telephone reports filed by state health de- 
partments and are summarized annually in the Morbidity and 
Mortality Weekly Report. NETSS provides no information on 
laboratory test results, clinical course, or patient outcome. Con- 
sequently, total mortality and CFR determinations for RMSF 
are derived solely from laboratory-confirmed cases reported to 
the CDC through case report forms [9]. 
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Starting in 1981, the CDC required the use of specific assays, 
including indirect immunofluorescence (IFA), indirect hemag- 
glutination, complement fixation, and latex agglutination in the 
serologic confirmation of all reported cases of RMSF [8, 13]. 
Serologic assays comprise the most widely available and fre- 
quently used methods for confirming cases of RMSF; however, 
these tests are often nonconfirmatory during the first 7-10 days 
of illness [13, 14]. In this report, we describe 9 patients with 
fatal RMSF for whom diagnoses were confirmed by immu- 
nohistochemical (IHC) staining of tissues for spotted fever 
group rickettsiae. Confirmatory serologic criteria were absent 
for all patients, underscoring the hidden mortality attributable 
to this disease and the value of histopathology and immuno- 
pathology in evaluating patients with suspected fatal RMSE 
Materials and Methods 
Patient samples. Formalin-fixed, paraffin-embedded tissues 
from 16 patients with suspected fatal RMSF were submitted to the 
CDC from May 1996 to December 1997 for laboratory confir- 
mation. For 12 of these patients, acute-phase serum samples were 
also available for testing. Unfixed tissues or whole blood collected 
at autopsy were available for testing for 5 cases. Routine hema- 
toxylin-eosin-stained tissue sections were examined for all cases. 
Clinical summaries, laboratory reports, and autopsy reports were 
reviewed when available. 
Immunohistochemistry. Tissues obtained at autopsy were tested 
for spotted fever group rickettsiae by use of a modified immu- 
noalkaline phosphatase technique [15]. In brief, 3-tm sections were 
deparaffinized in xylene, rehydrated in a graded alcohol series, and 
rinsed in distilled water. Tissue sections were digested in 0.1 mg/ 
mL proteinase K (Boehringer Mannheim, Indianapolis) for 15 min 
and blocked with 20% normal swine serum in Tris-saline-Triton 
(NSS/TST). Slides were incubated in a 1/500 dilution of polyclonal 
rabbit anti-Rickettsia rickettsii antiserum (complement fixation ti- 
ter of 1024, prepared as previously described [16]) for 60 min. The 
sections were washed three times in NSS/TST, incubated in bioti- 
nylated swine anti-mouse and anti-rabbit antibody (Dako, Car- 
penteria, CA) for 15 min, washed in NSS/TST, and incubated with 
alkaline phosphatase-conjugated streptavidin for 15 min. The 
slides were rinsed, incubated in naphthol phosphate-fast red chro- 
mogen reagent for 15 min, counterstained in Mayer's hematoxylin 
for 6 min, and mounted with aqueous mounting medium. 
The primary hyperimmune antiserum used in this assay dem- 
onstrates reactivity to multiple spotted fever group rickettsiae, in- 
cluding Rickettsia akari, Rickettsia conorii, and R. rickettsii [16]. 
The specificity of the anti-spotted fever group rickettsial antibody 
was confirmed in IHC experiments by demonstrating the absence 
of reactivity with normal patient tissues and with multiple tissues 
infected with nonrelevant bacterial pathogens, including Coxiella 
burnetii, Francisella tularensis, Ehrlichia chaffeensis, Ehrlichia equi, 
Legionella pneumophila type I, Neisseria meningitidis group C, 
Rickettsia typhi, Treponemapallidum, and Yersiniapestis. Similarly, 
nonimmune rabbit serum and several primary hyperimmune an- 
tisera to nonrelevant bacteria (as listed above) did not react with 
patient tissues that were positive as determined by IHC testing for 
spotted fever group rickettsiae. 
The IHC staining technique for spotted fever group rickettsiae 
was validated by use of autopsy-derived tissues from 7 patients 
with fatal RMSF in whom the diagnosis was confirmed by serologic 
testing (median IFA titer, 256; range, 64-1024), including 2 patients 
additionally tested by use of polymerase chain reaction (PCR) to 
confirm the 17-kDa rickettsial surface protein gene. 
IFA. Patient serum was diluted from 1/8 to 1/256 and evaluated 
for antibodies reactive with spotted fever group rickettsiae by use 
of IFA [17]. IgG and IgM antibodies were detected by use of flu- 
orescein isothiocyanate-conjugated goat anti-human IgG and IgM 
antibodies, respectively (Kirkegaard & Perry, Gaithersburg, MD). 
All IgM determinations were made after absorption of IgG, using 
the Quik-Sep IgM Protein G affinity method (Isolab, Akron, OH). 
End-point titers were recorded as the reciprocal of the highest di- 
lution exhibiting specific rickettsial fluorescence. Patients with a 
reciprocal IFA titer >64 were considered seropositive [12]. 
Nucleic acid amplification and sequencing. Extraction kits 
(QIAGEN, Chatsworth, CA) were used to obtain DNA from 200 
jiL of EDTA-anticoagulated whole blood and from 0.2 x 0.2 x 0.2 
cm fragments of fresh tissues obtained at autopsy. Extracts were 
evaluated by use of a nested PCR assay designed to amplify a 246- 
bp segment of the 17-kDa rickettsial surface protein gene from 
whole blood and unfixed tissues [18] (DB McKechnie, unpublished 
data). This assay has not been optimized to evaluate formalin-fixed 
tissues, and no fixed tissue samples were evaluated. In brief, 10 ItL 
of extracted DNA was amplified in a 100-jiL primary reaction, 
using 0.5 ,LM each of primers R17.126 and R17.507. One /L 
of 
the primary reaction mix was amplified in a 100-/iL 
nested reaction, 
using 0.2 CM each of primers TZ15 and TZ16 [19]. Primary re- 
actions (40 cycles) and nested reactions (30 cycles) were performed 
in a thermal cycler (GeneAmp Systems 9600; Perkin-Elmer, Foster 
City, CA), with a profile consisting of denaturation at 95rC for 2 
min, followed by denaturation at 940C for 30 s, annealing at 550C 
for 30 s, extension at 720C for 1 min, and an additional extension 
for the last cycle at 720C for 5 min. PCR products were sequenced 
by use of the dideoxy terminator system on an automated sequencer 
(ABI Prism 377; Applied Biosystems, Foster City, CA) and ana- 
lyzed with computer software (Wisconsin Sequence Analysis Pack- 
age; Genetics Computer Group, Madison). 
Review of RMSF case report forms. RMSF case report forms 
submitted by state health departments to the CDC for years 
1981-1996 were reviewed to assess the magnitude of total con- 
firmed cases and confirmed fatalities in national reporting of 
RMSE Confirmed cases met one or more of the Council of State 
and Territorial Epidemiologists criteria for RMSF [12]: (1) a >-4- 
fold change in titer of antibody reactive with R. rickettsii by IFA, 
latex agglutination, complement fixation, or indirect hemagglutin- 
ation tests; (2) the detection of R. rickettsii DNA by PCR; (3) the 
demonstration of R. rickettsii in biopsy or autopsy tissues by spe- 
cific immunostains, including immunofluorescence, immunoperox- 
idase, and immunoalkaline phosphatase stains; and (4) the isolation 
of R. rickettsii from a clinical specimen. In addition, patients with 
a single titer >64 by IFA or > 16 by complement fixation were 
categorized as confirmed cases for the purpose of surveillance [9]. 
Total numbers of fatal cases confirmed by serology, immunopath- 
ology, PCR, or isolation were compared to determine the relative 
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frequencies of each test category used to establish the diagnosis of 
RMSF during this 16-year interval. The median number of days 
from onset of disease to death was determined for all laboratory- 
confirmed cases of RMSF reported in during 1981-1996. 
Results 
Results of confirmatory tests for RMSF RMSF was con- 
firmed in 12 of 16 deceased patients on the basis of IHC testing 
alone or in combination with serology or PCR. None of the 4 
patients for whom IHC results were negative had a positive 
serology or PCR result. All 12 laboratory-confirmed cases had 
unequivocal IHC evidence of rickettsial antigen in tissues. 
Three of the 12 IHC-confirmed RMSF fatalities additionally 
demonstrated serum antibody reactive with R. rickettsii at titers 
>64 and are not included in further discussion. Nine patients 
had positive IHC results with either a negative or unavailable 
serologic result (table 1). Acute-phase serum samples were avail- 
able for 7 of 9 patients evaluated in the series. For 2 (patients 
5 and 6), RMSF was not considered before autopsy; serum for 
these patients was not collected and therefore was unavailable 
for testing. Serum specimens were obtained a median of 5 days 
(range, 2-8) following onset of illness. None of the 7 samples 
demonstrated specific IgG or IgM antibodies reactive to R. 
rickettsii at a dilution > 1/64. None of these patients met Coun- 
cil of State and Territorial Epidemiologists or CDC surveillance 
criteria for serologically confirmed RMSF [9, 12] on the basis 
of the best recognized and most widely available confirmatory 
assay. 
Patient characteristics. Patients for whom IHC testing 
demonstrated spotted fever group rickettsiae in tissues but who 
lacked confirmatory serology for RMSF originated from eight 
states (Alabama, Georgia, Kansas, Kentucky, Idaho, Missis- 
sippi, North Carolina, and West Virginia). There were 4 males 
and 5 females, who ranged in age from 2 months to 65 years 
(table 1). 
All patients presented with an acute febrile illness during 
April-October. Myalgias and vomiting were reported in 6 and 
7 of these patients, respectively. A macular or petechial rash 
(or both) was reported for 6 patients, and headache was re- 
ported for 3. The triad of fever-rash-headache was identified 
for 3 patients. A history of tick bite preceding the illness was 
described for 5 patients. The triad of fever-rash-tick bite was 
identified for 3 patients. Thrombocytopenia (range, 14,000- 
72,000/IpL) was reported in 8 patients. One or more electrolyte 
abnormalities were described for 7 patients, including hypona- 
tremia (serum sodium 134 mEq/L), hypocalcemia (serum cal- 
cium <8.6 mEq/L), and hypokalemia (serum potassium <3.1 
mEq/L) in 4, 4, and 3 patients, respectively. Aspartate ami- 
notransferase levels were elevated (i>136 IU/L) in 4 patients. A median of 7 days (range, 5-10) elapsed from onset of symp- 
toms to death. Fulminant RMSF (i.e., death occurring in the 
first 5 days of illness [20]) was reported for 2 patients. RMSF 
was considered in the premortem differential diagnosis in 3 
patients, and 4 patients received antimicrobial therapy active 
against R. rickettsii (doxycycline for 3, chloramphenicol for 1) 
before their deaths. 
Immunohistochemistry. A minimum of 4 tissues from each 
patient were evaluated by IHC staining. Tissues (no. of patients) 
included liver (9), myocardium (8), spleen (8), kidney (8), lung 
(7), adrenal gland (5), pancreas (5), cerebral cortex (5), cere- 
bellum (4), skin (4), stomach (4), colon (4), bone marrow (3), 
lymph node (3), small intestine (2), trachea (2), skeletal muscle 
(2), thymus (2), and thyroid (2). The following tissue types were 
represented as single samples from patients in the series: cor- 
onary artery, aorta, hippocampus, medulla, pons, pineal gland, 
choroid plexus, ovary, tongue, and appendix. A bone marrow 
biopsy obtained 1 day before death was available for 1 patient 
(patient 7). 
Rickettsial antigens reactive with the anti-R. rickettsia an- 
tibody stain were visualized in multiple tissues from each patient 
(table 1). Staining was most apparent within and associated 
Table 1. Patient characteristics and confirmatory laboratory findings in persons with fatal, serologically 
unconfirmed Rocky Mountain spotted fever. 
Reciprocal 
IFA titer No. of days from onset of No. of days from onset of 
Patient Age, sex illness to death illness to serum sample IgG IgM PCR IHC 
1 28 years, F 6 5 <8 <8 NA + 
2 19 years, M 10 8 32 32 NA + 
3 29 years, F 5 4 <8 <8 NA + 
4 65 years, F 7 7 32 16 + + 
5 58 years, F 9 NA NA NA NA + 
6 49 years, M 7 NA NA NA + + 
7 35 years, M 5 5 <8 16 NA + 
8 3 years, F 7 7 <8 <8 NA + 
9 2 months, M 6 2 <8 <8 NA + 
NOTE. IFA = indirect immunofluorescence assay; PCR = polymerase chain reaction amplification of rickettsial 
17-kDa surface protein gene sequence from whole blood or unfixed patient tissues collected at autopsy; IHC = 
immunoalkaline phosphatase stain for spotted fever group rickettsiae, including Rickettsia rickettsii, in formalin-fixed, 
paraffin-embedded tissues obtained at autopsy; NA = serum, whole blood, or unfixed tissue samples unavailable for 
testing. 
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with vascular endothelium of capillaries, arterioles, venules, ar- 
teries, and veins (figure 1A-D). Rickettsial antigens and discrete 
coccobacilli were primarily located within the cytoplasm and 
occasionally in nuclei of infected endothelial cells (figure 1A-C); 
less frequently, they were located within fixed and circulating 
mononuclear phagocytic cells, including bone marrow histio- 
cytes (figure ID), Kupffer's cells, pulmonary alveolar macro- 
phages, and monocytes. Aggregates of fragmented, granular, 
or coalesced rickettsial antigens were occasionally seen in foci 
of intense staining (figure IB). Abundant extracellular rickett- 
sial antigen was distributed throughout the splenic red pulp in 
5 of 8 patients for whom spleen was examined by IHC staining. 
Although observations were generally limited to evaluation 
of a single section representing a particular organ, tissues 
stained with hematoxylin and eosin frequently revealed lym- 
phohistiocytic infiltrates around and involving small vessels, 
which subsequently demonstrated abundant rickettsial antigen 
by IHC staining. Inflammatory lesions identified by routine 
staining included hepatic portal triaditis (9/9 patients), focal 
interstitial pneumonitis (7/7 patients), meningitis (5/7 patients), 
interstitial nephritis (4/8 patients), focal myocarditis (4/8 pa- 
tients), and focal vasculitis in the dermis (4/4 patients). 
Rickettsiae were also identified in minimally inflamed or non- 
inflamed vessels, and intensely inflamed foci occasionally failed 
to demonstrate stainable bacteria. Rickettsial antigens were 
characteristically distributed as discontinuous foci in vessels in 
each of the major organs examined. Rickettsiae were identified 
in or around small vessels in sections of skin from each patient 
for whom this tissue was available; however, the organisms were 
often sparse and distributed sporadically in the tissue. Other 
frequently observed lesions included pulmonary intra-alveolar 
hemorrhage (7/7 patients), erythrophagocytosis by Kupffer's 
cells (6/9 patients), and microscopic cortical necroses in the 
adrenal glands (3/5 patients). Multifocal arteriolar microin- 
farcts or glial nodules involving the cerebral cortex and brain- 
stem were seen in 3 of 7 patients in this series. 
Figure 1. Immunohistochemical localization of spotted fever group rickettsial antigens in tissues of patients with fatal Rocky Mountain spotted 
fever. Immunoalkaline phosphatase stain with naphthol phosphate-fast red substrate and hematoxylin counterstain. A, Intracytoplasmic and 
intranuclear spotted fever group rickettsiae in infected endothelial cells in white matter of cerebral cortex (patient 2); original magnification, x 158. 
B, Rickettsia rickettsii within damaged endothelium of dermal capillary (patient 4); original magnification, x 158. C, Coccobacillary forms of 
R. rickettsii in cytoplasms of infected endothelial cells in a leptomeningeal vein (patient 6); original magnification, X250. D, Rickettsiae in 
cytoplasms of bone marrow histiocytes (patient 7); original magnification, x 158. 
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Nucleic acid amplification from patient blood and tissues. 
Rickettsial 17-kDa gene sequences were amplified from blood 
or fresh tissues of all 4 of the 12 IHC assay-positive patients 
for whom appropriate samples were obtained. These included 
2 of the 9 serologically unconfirmed patients. For each case 
with unfixed tissues available for evaluation, PCR analysis val- 
idated the IHC results. PCR products of the expected size were 
amplified from peripheral blood, spleen, and liver of patient 4 
and from skeletal muscle and myocardium of patient 6. Se- 
quence analysis of 208 bp of the amplicons was used to verify 
17-kDa rickettsial surface protein gene sequences; they dem- 
onstrated 100% homology to the corresponding sequence of R. 
rickettsii (GenBank accession no. M16486). 
RMSF fatalities reported in the United States, 1981-1996. 
Case report forms that were submitted to the CDC for 
1981-1996 were reviewed: 5388 (57.9%) of 9312 forms revealed 
laboratory-confirmed cases of RMSF (209-602 cases/year), in- 
cluding 182 laboratory-confirmed fatalities (4-24 confirmed fa- 
talities/year). The mean annual CFR for this 16-year interval 
was 3.4% (range, 1.2%--5.3%). Of the total confirmed RMSF 
fatalities, 109 (59.8%) were diagnosed by serology, 67 (36.8%) 
by immunopathology, and 15 (8.2 %) by PCR or isolation of 
R. rickettsii (table 2). Ninety-two (33.6%) of 274 deaths re- 
ported to the CDC during this period were unconfirmed by 
laboratory testing. For 159 laboratory-confirmed deaths during 
1981-1996 for which dates of onset and dates of death were 
reported, the median time to death was 8 days; 107 (67%) of 
these deaths occurred in the first 9 days of illness. For labo- 
ratory-confirmed eaths occurring during 1981-1984 (65 pa- 
tients) and during 1993-1996 (20 patients), the median time to 
death was also 8 days. 
Discussion 
The epidemiologic and clinical characteristics of the 9 pa- 
tients described in this report were strongly compatible with 
RMSF. All patients resided in areas where R. rickettsii was 
endemic, became ill in mid-spring to early fall, and presented 
with an acute febrile syndrome characterized by myalgias, vom- 
iting, and/or rash. The IFA, which was used to detect anti- 
rickettsial antibody, determined that none of the 9 patients 
examined in this series fulfilled CDC surveillance criteria for 
laboratory-confirmed RMSE Had IFA been the only test at- 
tempted, none of these 9 fatalities would be included in yearly 
CFR estimates for RMSF. We detected 12 fatal cases that were 
identified by IHC staining in a 14-month interval from 1996 
through 1997. By comparison, immunopathology was used to 
confirm only 9 of 38 RMSF deaths reported to the CDC during 
1991-1995 (table 2). These data suggest that IHC staining is 
underrecognized and underutilized as a diagnostic tool and that 
many, if not most, deaths caused by R. rickettsii n the United 
States are missed, unconfirmed, or unreported. 
Detection of antibody to spotted fever group rickettsiae re- 
Table 2. Laboratory-confirmed cases of fatal Rocky Mountain spot- 
ted fever reported to the Centers for Disease Control and Prevention 
(CDC), 1981-1996. 
Laboratory criteria for 
Total no. of confirmation of fatal casesb laboratory- 
confirmed Case-fatality Immuno- 
Year cases ratio (%)a Serologyc pathologyd Othere 
1981 369 13/341 (3.8) 5 7 1 
1982 399 20/379 (5.3) 13 7 1 
1983 602 24/553 (4.3) 14 10 4 
1984 398 19/361 (5.3) 14 5 1 
1985 334 16/320 (5.0) 9 6 2 
1986 346 11/325 (3.4) 3 7 1 
1987 257 5/241 (2.1) 3 2 0 
1988 362 15/348 (4.3) 14 2 0 
1989 299 4/274 (1.5) 2 2 0 
1990 300 13/263 (4.9) 4 8 1 
1991 289 8/254 (3.1) 3 4 2 
1992 263 8/227 (3.5) 6 2 0 
1993 209 9/192 (4.7) 6 3 0 
1994 270 8/204 (3.9) 6 0 2 
1995 325 5/294 (1.7) 5 0 0 
1996 366 4/348 (1.2) 2 2 0 
NOTE. Data were determined from RMSF case report forms ubmitted by 
state health departments to the CDC. 
a Case-fatality ratios determined from confirmed cases for which patient out- 
come (i.e., fatal or nonfatal) is specified; 8.6% of case report data are incomplete 
and do not designate patient outcome. b Laboratory criteria defined by Council of State and Territorial Epidemiol- 
ogists [12]. Total no. of laboratory confirmations may exceed total no. of con- 
firmed fatalities when multiple assays are used to establish diagnosis. c Includes indirect immunofluorescence, lat x agglutination, complement fix- 
ation, and indirect hemagglutination assays for detecting antibodies reactive with 
Rickettsia rickettsii. d Includes immunofluorescence, immunoperoxidase, and immunoalkaline 
phosphatase stains for detecting spotted fever group rickettsiae intissues. 
e Includes polymerase chain reaction assay or isolation of R. rickettsii from 
patient blood or tissues. 
mains the best recognized and most utilized laboratory method 
to confirm RMSF The IFA test is generally considered the 
reference standard in RMSF serology [13] and is the test cur- 
rently used by the CDC and most state public health labora- 
tories. Most patients with RMSF lack diagnostic IFA titers 
(i.e., >64) until the second week of disease, an observation 
supported by studies of patients with strong clinical and epi- 
demiologic evidence of RMSF [21, 22], culture-confirmed R. 
rickettsii infection [23, 24], and t>4-fold changes in antibody titer over the course of their illness [25]. IFA titers > 16 may 
appear within 5-6 days after onset of symptoms [14]; however, 
<15% of patients demonstrate IgG or IgM titers >64 in the 
first 7 days of illness [21]. About 40%-50% of patients lack a 
diagnostic titer 7-9 days after onset of illness [13, 14], and as 
many as 25% of all patients with RMSF lack a diagnostic titer 
by the end of the second week of disease [13, 21]. 
The kinetics of the serologic response to infection with R. 
rickettsii is particularly important in view of the temporal 
course of fatal RMSF. Treatises on this disease from the 1930s 
and 1940s reported the majority of deaths to occur in the second 
and third weeks of illness [20, 26]. Patients in our series died 
of RMSF a median of 7 days following onset of illness, which 
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is in agreement with many contemporary case series, in which 
at least half of all deaths occur within the first 7-9 days of the 
disease [10, 27-29]. In the present study, deaths reported during 
1981-1996 occurred a median of 8 days after onset of symp- 
toms. These findings are consistent with some of the earliest 
descriptions of the clinical course of disease: 43 (49%) of 88 
spotted fever deaths reported by Wilson and Chowning in 1904 
died within the first 8 days of illness, and 65 (68%) of these 
patients died 6-10 days after onset of symptoms [2]. 
In this context, it could be reasonably expected that >50% 
of all patients with fatal RMSF lack diagnostic antibody at the 
time of death. In a 1978 study of 44 deaths attributable to 
RMSF, <25% of cases demonstrated confirmatory serologic ev- 
idence of infection with R. rickettsii [6]. Reporting of RMSF 
primarily on the basis of antibody-detection diagnostics will 
underestimate the absolute number of RMSF deaths, although 
the effect on the CFR is less clearly defined. The CFR depends 
both on the appropriate identification of fatal cases and on a 
positive test for a case to enter the denominator. Because many 
cases are confirmed for surveillance reports on the basis of one 
positive laboratory test (most often a serologic test) in the pres- 
ence of clinically compatible disease, patients who survive their 
infection but are tested early in the disease course may be 
missed. Perseverance by physicians to obtain convalescent- 
phase serum will certainly assist in accurately defining the total 
number of cases among persons who survive the disease; how- 
ever, this is not an option in fatal cases. Unless methods other 
than serology are attempted in patients with fatal RMSF, the 
number of deaths attributable to this disease will be underes- 
timated. In the past 16 years, however, confirmatory methods 
other than serology (i.e., immunopathology, PCR, or isolation) 
have been used to diagnose <40% of the RMSF fatalities re- 
ported to the CDC (table 2). 
In this case series, lesions were regularly observed in sections 
of kidney, heart, lung, liver, and skin by use of routine he- 
matoxylin and eosin staining, and rickettsiae were consistently 
identified in these anatomic locations by use of IHC staining. 
Although no single lesion is pathognomonic for RMSF [30], a 
number of histopathologic findings are recognized and may 
suggest subsequent IHC evaluation for rickettsiae. Suggestive 
pathology observed in this study and documented in previous 
series includes multifocal lymphohistiocytic infiltrates in the 
interstitium of the kidneys [27, 31, 32], heart [33, 34], and lung 
[35, 36] and in the hepatic portal triads [37, 38]. Adrenal cortical 
necroses were identified in several patients in this series and 
characteristically contained abundant rickettsial antigens. Mul- 
tifocal necroses may be observed in the adrenal cortices of per- 
sons dying of RMSF [39-41], and adrenal glands of these pa- 
tients often contain rickettsiae [36, 38]. Skin represents the most 
accessible organ for histopathologic and IHC evaluation of 
RMSF; however, rickettsial antigens are often distributed spo- 
radically in this tissue, and even relatively large segments of 
skin obtained at autopsy from patients with petechial or ec- 
chymotic lesions may demonstrate broad areas with no de- 
monstrable rickettsiae [39, 42, data herein]. 
Lesions involving the central nervous system, including mul- 
tifocal glial nodules and arteriolar microinfarcts, are among the 
most suggestive histopathologic features of RMSF [30]. How- 
ever, these findings are seldom observed in patients who die 
before day 11 of illness [43]. Glial nodules and arteriolar mi- 
croinfarcts were observed together in a patient in this series 
who died on day 10 after onset; however, these lesions would 
probably be absent in most patients with serologically uncon- 
firmed disease. In several of the patients in this series, typical 
mononuclear inflammatory lesions were minimal, yet IHC 
staining revealed numerous organisms. This was particularly 
true in the patients who died early in the course of disease, 
which is in agreement with previous descriptions of the pa- 
thology in patients with fulminant RMSF [41]. 
With remarkably few exceptions, pathologists have had dif- 
ficulty demonstrating rickettsiae in patient tissues by use of 
conventional histochemical methods. Even tissues stained with 
classical stains for Rickettsia species (e.g., Giemsa, Macchia- 
vellos, and Pinkerton's stains) are characteristically difficult o 
interpret and may produce misleading results [30]. Immunologic 
staining techniques for detecting R. rickettsii revolutionized the 
detection of these organisms in patient tissues and have been 
used in diagnostic capacities since 1976. Previous studies have 
emphasized the clinical utility of immunostaining of skin biopsy 
specimens to guide patient care in suspected cases of RMSF 
[44-49] or as a method to investigate the pathophysiology of 
RMSF by evaluating the anatomic distribution of rickettsial 
antigens in specific organs, including kidney [31, 32, 42], heart 
[33], lung [35, 36], skin [47-50], liver [37, 38], stomach, small 
intestine, colon, and pancreas [51]. These stains additionally 
represent powerful tools for use in confirming fatal spotted 
fever infection [39, 52, 53]. In this context, IHC staining for R. 
rickettsii may uncover otherwise undiagnosed RMSF fatalities, 
particularly when conventional samples (e.g., acute-phase se- 
rum and whole blood) may not be available. As an example, 
IHC staining has been used to diagnose a fatal rickettsial in- 
fection from archived tissues nearly a century old [53]. 
Abundant, intensely staining rickettsial antigens were iden- 
tified in multiple tissues from all patients in this series, including 
tissues from all 4 patients receiving specific antirickettsial ther- 
apy. Antimicrobial therapy may diminish or even abrogate the 
detection of rickettsiae by IHC staining. Morphologic disrup- 
tion and scarcity of rickettsiae have been observed in skin bi- 
opsy specimens after 24-48 h of tetracycline or chloramphenicol 
therapy [45], and positive immunostaining has not been pre- 
viously described in biopsy or autopsy tissues from patients 
receiving >48 h of therapy [30-32, 42, 48]. In this study, discrete 
coccobacilli were visualized in sections from multiple organs in 
patients receiving > 1 days of antirickettsial therapy, including 
1 patient who received doxycycline for 72 h (figure 1A). Au- 
topsy-derived tissues may be less susceptible to antibiotic-in- 
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duced false-negative reactivity because of increased numbers of 
rickettsiae and larger areas of tissue available for evaluation. 
The duration of therapy necessary to abolish immunologic de- 
tection of R. rickettsii in patient tissues may ultimately vary by 
tissue type, bacterial load, or sensitivity of the assay. However, 
the inability of immunostaining to detect rickettsial antigens in 
autopsy tissues after 5-7 days of antirickettsial therapy has been 
documented consistently [30-32, 35]. 
Epidemiologic and clinical clues should be fundamental in 
guiding requests for IHC testing. Reasonable contexts for use 
of this assay include any unexplained, fatal, febrile illness char- 
acterized by (1) occurrence of disease between early spring and 
late summer, particularly in recognized R. rickettsii-endemic 
regions (observed in 8/9 patients in this series), (2) a clinical 
course that includes thrombocytopenia in combination with a 
macular or petechial rash, elevated hepatic transaminase levels, 
or electrolyte abnormalities (observed in 7/9 patients in this 
series), or (3) a history of tick bite preceding the illness (ob- 
served in 5/9 patients in this series). Although lymphohistiocytic 
infiltrates involving small vessels are often identified in 
t>1 
tis- 
sues, the histopathology of fatal RMSF may be subtle or rep- 
resented as nonspecific findings, such as hepatic erythrophag- 
ocytosis, adrenal necroses, or pulmonary intra-alveolar 
hemorrhage. The diagnostic dilemma posed by fulminant 
RMSF may be even greater [30]. In these settings, clinical and 
epidemiologic clues gleaned from the patient history and hos- 
pital course assume considerable importance for the pathologist 
and clinician. 
An accurate count of mortality attributable to RMSF re- 
mains elusive. The CDC determines the number of deaths and 
the CFR for RMSF from data provided by case report forms, 
and underreporting of fatal cases may contribute to falsely low 
mortality estimates. Although RMSF is a nationally notifiable 
disease, many cases are missed or unreported. Prospective active 
surveillance for RMSF in regions where the disease is hyper- 
endemic suggests that as many as 50% of all cases (including 
confirmed but unreported deaths due to RMSF) are missed by 
passive surveillance mechanisms (e.g., NETSS and case report 
forms) [54]. 
Phenomena independent of reporting error may also con- 
tribute to recent declines in CFRs. The requirement of rigorous 
laboratory criteria has understandably reduced the number of 
confirmed fatalities attributable to RMSF; one-third of all 
deaths reported during 1981-1996 were unconfirmed by lab- 
oratory assays. The effect of more stringent confirmatory cri- 
teria on the CFR is less clear, as 42% of the 9312 RMSF "cases" 
reported to the CDC through case report forms during 
1981-1996 were classified as probable or unconfirmed. During 
this same interval, expanding physician awareness of Borrelia 
and Ehrlichia infections has resulted in broader use of anti- 
rickettsial therapies, particularly the use of doxycycline in feb- 
rile patients with a history of tick bite. Prompt administration 
of effective antimicrobials in misdiagnosed yet appropriately 
treated cases of RMSF may indirectly and fortuitously lower 
deaths and possibly CFRs associated with this disease. 
Regardless of real and artifactual influences on RMSF death 
statistics, confirmation of fatal disease remains fundamental in 
compiling accurate mortality data. We believe that this process 
is greatly augmented by immunopathology. Immunostaining 
for spotted fever group rickettsiae is offered by the CDC and 
a few state health departments and university-based hospital 
and commercial laboratories in the United States. Increased 
awareness and availability of these assays will enhance efforts 
to better define mortality attributable to RMSE Additionally, 
by diagnosing otherwise unconfirmed or unexplained deaths, 
immunopathology can help identify foci of endemicity for R. 
rickettsii and promote awareness, prevention, and early rec- 
ognition of this severe and potentially lethal disease. 
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